All News

Found 233 articles

• Kura Oncology Reports Second Quarter 2021 Financial Results

  8/5/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported second quarter 2021 financial results and provided a corporate update.

• Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

  8/5/2021

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported financial results for the second quarter ended June 30, 2021, and recent operational highlights.

• Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

  8/4/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.

• Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

  7/29/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced the appointment of industry veteran Helen Collins, M.D., to its board of directors.

• Kura Oncology to Report Second Quarter 2021 Financial Results

  7/29/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021.

• Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

  7/19/2021

  Janux Therapeutics, Inc. today announced the appointment of Shahram Salek-Ardakani, Ph.D., as Chief Scientific Officer.

• 

  Clinical Catch-Up: July 5-9

  7/12/2021

  Last week presented a fair number of clinical trial news. Read on for more information.
• 

  Arbutus Forges HBV Collaboration with Vaccitech; Kura Partners with Novartis in Oncology

  7/6/2021

  Arbutus Biopharma forged a clinical collaboration with U.K.-based Vaccitech plc to develop a new treatment for people infected with chronic hepatitis B virus who are already receiving standard-of--care therapy.

• Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

  7/6/2021

  Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors.

• 

  Clinical Catch-Up: June 21-25

  6/28/2021

  It was a busy week for clinical trial news. Here’s a look.

• Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

  6/24/2021

  – Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients.

• Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

  6/24/2021

   Intellia Therapeutics, Inc. today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary.

• Kura Oncology to Participate in JMP Securities Life Sciences Conference

  6/10/2021

  Kura Oncology, Inc. today announced its participation in the JMP Securities Life Sciences Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Thursday, June 17, 2021.

• Kura Oncology Appoints Carol Schafer to Board of Directors

  6/4/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021.

• Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

  5/13/2021

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.

• Kura Oncology Reports First Quarter 2021 Financial Results

  5/6/2021

  Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window

• Kura Oncology to Report First Quarter 2021 Financial Results

  4/29/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the close of U.S. financial markets on Thursday, May 6, 2021.

• Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments

  4/20/2021

  Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.

• BioTheryX Announces Expansion of Scientific Advisory Board

  4/7/2021

  BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D. 

• Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

  3/22/2021

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of results from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy